Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
Top Cited Papers
Open Access
- 11 February 2005
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 5 (3), 443-453
- https://doi.org/10.1111/j.1600-6143.2005.00749.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003
- CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast KineticsThe Journal of Experimental Medicine, 1997
- Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory InteractionsJournal of Biological Chemistry, 1996
- The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells.The Journal of Experimental Medicine, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.The Journal of Experimental Medicine, 1995
- Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.The Journal of Experimental Medicine, 1994
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994
- Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.The Journal of Experimental Medicine, 1992